Glypican-1 facilitates prion conversion in lipid rafts

被引:19
|
作者
Hooper, Nigel M. [1 ]
机构
[1] Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England
基金
英国医学研究理事会; 英国惠康基金;
关键词
glycosaminoglycan; glypican; heparan sulphate; lipid raft; prion; CREUTZFELDT-JAKOB-DISEASE; HEPARAN-SULFATE PROTEOGLYCANS; BLOOD-TRANSFUSION; AMYLOID PLAQUES; SCRAPIE ISOFORM; DEXTRAN SULFATE; CULTURED-CELLS; PROTEIN; PRP; GLYCOSAMINOGLYCANS;
D O I
10.1111/j.1471-4159.2010.06936.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The conformational conversion of the cellular prion protein (PrPC) to the infectious form (PrPSc) is the critical step in the pathogenesis of prion diseases such as Creutzfeldt-Jakob disease in humans and scrapie in sheep. Cholesterol-rich lipid rafts play a key role in the conversion of PrPC to PrPSc and other cellular components have been identified as important cofactors to trigger, enhance, or accelerate prion formation. Amongst these heparan sulphate proteoglycans (HSPGs) and their glycosaminoglycan side-chains have been implicated in prion metabolism. Recently, the cell-surface HSPG glypican-1 was demonstrated to co-localise with PrPC on the cell surface and to promote its association with lipid rafts. Both PrPC and PrPSc co-immunoprecipitated with glypican-1 and the interaction was dependent on the glycosaminoglycan side chains of glypican-1. Critically, depletion of glypican-1 in scrapie-infected N2a cells reduced the formation of PrPSc, indicating that this HSPG is involved in prion formation. Further work is required to understand the molecular and cellular mechanisms underpinning the role of glypican-1 and possibly other members of the glypican family in prion metabolism, and to determine whether glypican-1 facilitates PrPSc formation in vivo.
引用
收藏
页码:721 / 725
页数:5
相关论文
共 50 条
  • [31] The place of lipid rafts in the turbulent life of prion protein
    Morris, R.
    Parkyn, C.
    Vermeulen, E.
    Mootoosamy, R.
    Chen, X.
    Jen, A.
    JOURNAL OF NEUROCHEMISTRY, 2006, 99 : 20 - 20
  • [32] Glypican-1 as a novel immunotherapeutic target in prostate cancer.
    Zaslavsky, Alexander
    Adams, Mackenzie
    Wissmueller, Sandra
    Campbell, Douglas
    Klingemann, Hans
    Walsh, Brad
    Palapattu, Ganesh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [33] Glypican-1 as a Therapy Target in Esophageal Squamous Cell Carcinoma
    Song, Qingcui
    DIGESTIVE DISEASES AND SCIENCES, 2019, 64 (11) : 3355 - 3356
  • [34] Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target
    Sabanathan, Dhanusha
    Lund, Maria E.
    Campbell, Douglas H.
    Walsh, Bradley J.
    Gurney, Howard
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [35] Expression of the heparan sulfate proteoglycan glypican-1 in the developing rodent
    Litwack, ED
    Ivins, JK
    Kumbasar, A
    Paine-Saunders, S
    Stipp, CS
    Lander, AD
    DEVELOPMENTAL DYNAMICS, 1998, 211 (01) : 72 - 87
  • [36] S-Nitrosylation of secreted recombinant human glypican-1
    Gabriel Svensson
    Katrin Mani
    Glycoconjugate Journal, 2009, 26 : 1247 - 1257
  • [37] Glypican-1表达的研究现状与进展
    张立霞
    刘冬青
    生理科学进展, 2020, 51 (02) : 103 - 106
  • [38] Glypican-1 as a Therapy Target in Esophageal Squamous Cell Carcinoma
    Qingcui Song
    Digestive Diseases and Sciences, 2019, 64 : 3355 - 3356
  • [39] Mechanisms underlying preferential assembly of heparan sulfate on glypican-1
    Chen, RL
    Lander, AD
    GLYCOBIOLOGY, 1999, 9 (10) : 1133 - 1133
  • [40] Role of glypican-1 in regulating multiple cellular signaling pathways
    Pan, Jiajia
    Ho, Mitchell
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2021, 321 (05): : C846 - C858